672 related articles for article (PubMed ID: 19165225)
21. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
22. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations.
Merkle FT; Ghosh S; Kamitaki N; Mitchell J; Avior Y; Mello C; Kashin S; Mekhoubad S; Ilic D; Charlton M; Saphier G; Handsaker RE; Genovese G; Bar S; Benvenisty N; McCarroll SA; Eggan K
Nature; 2017 May; 545(7653):229-233. PubMed ID: 28445466
[TBL] [Abstract][Full Text] [Related]
23. A single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab population.
Alshatwi AA; Hasan TN; Shafi G; Alsaif MA; Al-Hazzani AA; Alsaif AA
Fundam Clin Pharmacol; 2012 Jun; 26(3):438-43. PubMed ID: 21477265
[TBL] [Abstract][Full Text] [Related]
24. Polymorphic variants in the p53 pathway.
Murphy ME
Cell Death Differ; 2006 Jun; 13(6):916-20. PubMed ID: 16557270
[No Abstract] [Full Text] [Related]
25. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
Manoharan V; Karunanayake EH; Tennekoon KH; De Silva S; Imthikab AIA; De Silva K; Angunawela P; Vishwakula S; Lunec J
BMC Cancer; 2020 Jan; 20(1):72. PubMed ID: 32000721
[TBL] [Abstract][Full Text] [Related]
26. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.
Bouaoun L; Sonkin D; Ardin M; Hollstein M; Byrnes G; Zavadil J; Olivier M
Hum Mutat; 2016 Sep; 37(9):865-76. PubMed ID: 27328919
[TBL] [Abstract][Full Text] [Related]
27. Targeting mutant p53 for efficient cancer therapy.
Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
[TBL] [Abstract][Full Text] [Related]
28. Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
Hori Y; Miyabe K; Yoshida M; Nakazawa T; Hayashi K; Naitoh I; Shimizu S; Kondo H; Nishi Y; Umemura S; Kato A; Ohara H; Inagaki H; Joh T
PLoS One; 2015; 10(3):e0118829. PubMed ID: 25734904
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the
Chitrala KN; Nagarkatti M; Nagarkatti P; Yeguvapalli S
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31216622
[TBL] [Abstract][Full Text] [Related]
30. Drug discovery and mutant p53.
Maslon MM; Hupp TR
Trends Cell Biol; 2010 Sep; 20(9):542-55. PubMed ID: 20656489
[TBL] [Abstract][Full Text] [Related]
31. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
32. Intratumour heterogeneity of p53 expression; causes and consequences.
Xue Y; San Luis B; Lane DP
J Pathol; 2019 Nov; 249(3):274-285. PubMed ID: 31322742
[TBL] [Abstract][Full Text] [Related]
33. Combining intracellular antibodies to restore function of mutated p53 in cancer.
Chan G; Jordaan G; Nishimura RN; Weisbart RH
Int J Cancer; 2016 Jan; 138(1):182-6. PubMed ID: 26174762
[TBL] [Abstract][Full Text] [Related]
34. Genetic Modifiers of the p53 Pathway.
Basu S; Murphy ME
Cold Spring Harb Perspect Med; 2016 Apr; 6(4):a026302. PubMed ID: 27037420
[TBL] [Abstract][Full Text] [Related]
35. Translating p53 into the clinic.
Cheok CF; Verma CS; Baselga J; Lane DP
Nat Rev Clin Oncol; 2011 Jan; 8(1):25-37. PubMed ID: 20975744
[TBL] [Abstract][Full Text] [Related]
36. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis.
Marcel V; Palmero EI; Falagan-Lotsch P; Martel-Planche G; Ashton-Prolla P; Olivier M; Brentani RR; Hainaut P; Achatz MI
J Med Genet; 2009 Nov; 46(11):766-72. PubMed ID: 19542078
[TBL] [Abstract][Full Text] [Related]
37. p53 Signaling Pathway Polymorphisms Associated With Emphysematous Changes in Patients With COPD.
Mizuno S; Ishizaki T; Kadowaki M; Akai M; Shiozaki K; Iguchi M; Oikawa T; Nakagawa K; Osanai K; Toga H; Gomez-Arroyo J; Kraskauskas D; Cool CD; Bogaard HJ; Voelkel NF
Chest; 2017 Jul; 152(1):58-69. PubMed ID: 28315337
[TBL] [Abstract][Full Text] [Related]
38. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
[TBL] [Abstract][Full Text] [Related]
39. Strategies for manipulating the p53 pathway in the treatment of human cancer.
Hupp TR; Lane DP; Ball KL
Biochem J; 2000 Nov; 352 Pt 1(Pt 1):1-17. PubMed ID: 11062053
[TBL] [Abstract][Full Text] [Related]
40. Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.
Herrero AB; Rojas EA; Misiewicz-Krzeminska I; Krzeminski P; GutiƩrrez NC
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]